OmniSeq Funding: How Much Did They Raise & Key Investors

How Much Did OmniSeq Raise?
Funding & Key Investors

OmniSeq, a specialized molecular diagnostic laboratory originating from the Roswell Park Comprehensive Cancer Center, has successfully secured a significant capital injection to bolster its clinical diagnostic capabilities. This major strategic investment, totaling $10M, underscores the firm's pivotal role in the evolving landscape of precision oncology. With a cumulative financial backing of $10M, the organization continues to solidify its market position as a leader in genomic and immune profiling, facilitating enhanced access to targeted cancer therapies for patients nationwide.

The recent infusion of capital serves as a testament to the company's operational maturity and its commitment to advancing diagnostic precision. By leveraging these resources, OmniSeq is well-positioned to scale its proprietary next-generation sequencing (NGS) platforms, ensuring that clinical decision-making is supported by robust, data-driven insights.

What is OmniSeq?

OmniSeq

Healthcare Services

Medical Laboratories & Imaging Centers

Based in Buffalo, New York, OmniSeq operates at the intersection of clinical research and patient care. The company specializes in molecular diagnostics, providing essential genomic and immune profiling services that assist oncologists in identifying the most effective treatment pathways or clinical trial opportunities for their patients. Its core product suite includes three distinct NGS-based assays: OmniSeq MSI NGS, OmniSeq Advance, and OmniSeq Comprehensive. These tools are designed to decode complex tumor biology, thereby enabling a more personalized approach to cancer management. By bridging the gap between laboratory innovation and bedside application, OmniSeq remains a critical component of the modern oncology ecosystem, helping to standardize the use of molecular data in routine clinical practice.

How much funding has OmniSeq raised?

OmniSeq has raised a total of $10M across 1 funding round:

2017

Debt

$10M

Debt (2017): $10M with participation from LabCorp

Key Investors in OmniSeq

LabCorp

Labcorp Holdings Inc. is a global leader in laboratory services, providing comprehensive diagnostic and biopharma laboratory solutions to support clinical decision-making for healthcare providers and patients.

What's next for OmniSeq?

Looking ahead, the strategic deployment of this financing will likely focus on the expansion of OmniSeq's diagnostic footprint and the further refinement of its NGS assay portfolio. As the demand for precision medicine continues to accelerate, the company is expected to prioritize the integration of its diagnostic services into broader healthcare networks, potentially enhancing its competitive advantage in the molecular testing market. The focus remains on improving patient outcomes through superior genomic intelligence, ensuring that the right drug or trial is matched to the right patient with increasing efficiency. Future growth trajectories will likely involve deeper collaborations with pharmaceutical partners and healthcare systems to standardize the adoption of comprehensive genomic profiling as a standard of care in oncology.

See full OmniSeq company page

See More Financial Insights